Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01034 (
cystatin C
)
3,397
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An artificial mutant Ala25Ser precursor
cystatin C
was created to help elucidate the cause of intracellular mis-localisation of the biochemically related variant B (Ala25Thr) precursor
cystatin C
to the mitochondria. Homozygotes of variant B precursor
cystatin C
were reported to carry an increased susceptibility to developing the exudative form of
AMD
. Ala25Ser precursor
cystatin C
shows a dual distribution to the Golgi apparatus and to the mitochondria. This localisation is thus intermediary between that of wild-type
cystatin C
(targeted to ER/Golgi compartment) and that of variant B precursor
cystatin C
. Furthermore, the level of secretion of Ala25Ser
cystatin C
by RPE cells is intermediary between wild type and variant B
cystatin C
. Ala25Ser precursor
cystatin C
thus represents a biochemical intermediate between the wild type and the
AMD
-associated
cystatin C
and as such, is a novel tool for the investigation of the mechanism of intracellular mis-localisation of variant B
cystatin C
. Our findings further support the hypothesis that substitution of the alanine residue in the penultimate position of precursor
cystatin C
signal sequence with a less hydrophobic amino acid residue, such as threonine (as in variant B
cystatin C
) or serine is sufficient to impair the intracellular trafficking and processing of the protein.
...
PMID:A dual Golgi- and mitochondria-localised Ala25Ser precursor cystatin C: an additional tool for characterising intracellular mis-localisation leading to increased AMD susceptibility. 1663 87
Age-related macular degeneration
(
AMD
) is a major cause of blindness worldwide. Oxidative stress plays a large role in the pathogenesis of
AMD
. The present study was to evaluate the effects of Fructus lycii ethanol extract on
AMD
in mice and to investigate whether combination of lutein and zeaxanthin, two carotenoid pigments in Fructus lycii, could protect human retinal pigment epithelial ARPE-19 cells treated with hydrogen peroxide (H2O2) in vitro. We found that severe sediment beneath retinal pigment epithelium and thickened Bruch membrane occurred in
AMD
mice. However, Fructus lycii ethanol extract improved the histopathologic changes and decreased the thickness of Bruch membrane. Furthermore, the gene and protein expression of cathepsin B and
cystatin C
was upregulated in
AMD
mice but was eliminated by Fructus lycii ethanol extract. Investigations in vitro showed that ARPE-19 cell proliferation was suppressed by H2O2. However, lutein/zeaxanthin not only stimulated cell proliferation but also abrogated the enhanced expression of MMP-2 and TIMP-1 in H2O2-treated ARPE-19 cells. These data collectively suggested that Fructus lycii ethanol extract and its active components lutein/zeaxanthin had protective effects on
AMD
in vivo and in vitro, providing novel insights into the beneficial role of Fructus lycii for
AMD
therapy.
...
PMID:Efficacy of Ethanol Extract of Fructus lycii and Its Constituents Lutein/Zeaxanthin in Protecting Retinal Pigment Epithelium Cells against Oxidative Stress: In Vivo and In Vitro Models of Age-Related Macular Degeneration. 2416 60
Age-related macular degeneration
(
AMD
) and Alzheimer's disease (AD) are degenerative, multifactorial diseases involving age-related accumulation of extracellular deposits linked to dysregulation of protein homeostasis. Here, we strengthen the evidence that an nsSNP (p.Ala25Thr) in the cysteine proteinase inhibitor
cystatin C
gene
CST3
, previously confirmed by meta-analysis to be associated with AD, is associated with exudative
AMD
. To our knowledge, this is the first report highlighting a genetic variant that increases the risk of developing both AD and
AMD
. Furthermore, we demonstrate that the risk associated with the mutant allele follows a recessive model for both diseases. We perform an
AMD
-
CST3
case-control study genotyping 350 exudative
AMD
Caucasian individuals. Bringing together our data with the previously reported
AMD
-
CST3
association study, the evidence of a recessive effect on
AMD
risk is strengthened (OR = 1.89, P = 0.005). This effect closely resembles the AD-
CST3
recessive effect (OR = 1.73, P = 0.005) previously established by meta-analysis. This resemblance is substantiated by the high correlation between
CST3
genotype and effect size across the two diseases (R(2) = 0.978). A recessive effect is in line with the known function of
cystatin C
, a potent enzyme inhibitor. Its potency means that, in heterozygous individuals, a single functional allele is sufficient to maintain its inhibitory function; only homozygous individuals will lack this form of proteolytic regulation. Our findings support the hypothesis that recessively acting variants account for some of the missing heritability of multifactorial diseases. Replacement therapy represents a translational opportunity for individuals homozygous for the mutant allele.
...
PMID:A missense variant in CST3 exerts a recessive effect on susceptibility to age-related macular degeneration resembling its association with Alzheimer's disease. 2589 95